Triheptanoin for the treatment of long‐chain fatty acid oxidation disorders: Final results of an open‐label, long‐term extension studyJerry Vockley, Antonio Nino Ramirez, Amarilis Sanchez‐Valle et al.|Journal of Inherited Metabolic Disease|2023Cited by 21
A Phase 1/2 first-in-human study to evaluate the safety, tolerability, and pharmacokinetics of UX053 in patients with glycogen storage disease type IIIDavid Rodriguez‐Buritica, Andrew Grimm, Tahseen Mozaffar et al.|Molecular Genetics and Metabolism|2024Cited by 0